All research
Semaglutide 2026-06-08 PubMed

Semaglutide reduces spinal implant infection and improves wound healing in murine Type 1 and Type 2 diabetes

Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide.

Background

Spinal surgery carries a significant risk of postoperative infection and wound complications, particularly in patients with diabetes mellitus (DM). Current standard-of-care often focuses on glycemic control, but the distinct pathophysiological contributions of Type 1 (T1DM) and Type 2 (T2DM) diabetes to infection susceptibility are rarely differentiated. This gap highlights the need for targeted therapies that address the specific immune dysregulation in each diabetic phenotype, potentially improving surgical outcomes beyond traditional approaches.

Study Design

Male C57BL/6J mice were used to model diabetes: T1DM was induced by streptozotocin, while T2DM was induced by a high-fat, high-sucrose diet. Spinal implants were surgically placed and then inoculated with bioluminescent Staphylococcus aureus to establish infection. Infection progression was tracked longitudinally using in vivo bioluminescence imaging. Systemic inflammation was characterized via multiplex cytokine profiling, and paraspinal tissues were analyzed post-mortem using histology and multiplex immunofluorescence. Diabetic cohorts received metabolic intervention with semaglutide (dose not specified in abstract) to assess therapeutic response.

Results

Both diabetic models consistently demonstrated greater infection burden and delayed wound healing compared to nondiabetic controls. Distinct inflammatory profiles emerged: T2DM was characterized by chronically elevated baseline inflammation and a blunted acute response to infection, whereas T1DM exhibited low baseline activity but an exaggerated and dysregulated cytokine induction post-infection. Treatment with semaglutide significantly:

attenuated infection severity, improved wound integrity, and partially normalized inflammatory patterns. Histology and immunofluorescence further corroborated these findings, revealing reduced immune cell infiltration and improved tissue organization in the semaglutide-treated cohorts, indicating a restoration of immune balance and enhanced tissue repair.

Key Findings

  • Diabetic mice (T1DM & T2DM) showed greater spinal implant infection burden and delayed wound healing.
  • T2DM mice exhibited chronically elevated baseline inflammation and a blunted acute immune response to infection.
  • T1DM mice displayed low baseline inflammation but an exaggerated and dysregulated cytokine induction post-infection.
  • Semaglutide treatment attenuated infection severity in both diabetic models.
  • Semaglutide improved wound integrity and partially normalized inflammatory patterns, reducing immune cell infiltration.

Why It Matters

These findings suggest that GLP-1 receptor agonists like semaglutide could serve as a novel adjunctive therapy to improve surgical outcomes in diabetic patients, particularly those undergoing spinal procedures. Beyond its established roles in glycemic control and weight management, semaglutide's ability to modulate immune responses and promote wound healing offers a new therapeutic avenue. This could lead to protocols where GLP-1RAs are administered perioperatively to mitigate infection risk and accelerate recovery, potentially reducing complications and healthcare burden in a vulnerable patient population. Further research is needed to translate these preclinical observations into human clinical practice.


semaglutide diabetes t1dm t2dm spinal infection wound healing
Source: pubmed:42253285 · Ingested 2026-06-08 · Digest: gemini-2.5-flash